Objective:To investigate the clinical efficacy and safety of Chuzhi Shengfa Tablets combined with ketoconazole shampoo and Chuzhi Shengfa Tablets combined with 5%minoxidil foam in the treatment of male androgenetic al...Objective:To investigate the clinical efficacy and safety of Chuzhi Shengfa Tablets combined with ketoconazole shampoo and Chuzhi Shengfa Tablets combined with 5%minoxidil foam in the treatment of male androgenetic alopecia.Methods:From July 2022 to July 2023,120 male patients with androgenetic alopecia were selected from our Department of Dermatology and randomly divided into Control Group 1,Control Group 2,Observation Group 1,and Observation Group 2,with 30 patients in each group.Control Group 1 was treated with ketoconazole shampoo,Control Group 2 with 5%minoxidil foam,Observation Group 1 with ketoconazole shampoo combined with Chuzhi Shengfa Tablets,and Observation Group 2 with 5%minoxidil foam combined with Chuzhi Shengfa Tablets.Hair density,hair diameter,scalp oil secretion(using oil secretion scoring),and adverse reactions were compared before and after treatment across the four groups.Results:After treatment,hair density and hair diameter significantly increased in all four groups compared to before treatment,while scalp oil secretion scores significantly decreased(P<0.05).The improvements in Observation Groups 1 and 2 were significantly better than those in Control Groups 1 and 2(P<0.05).No significant differences in the incidence of adverse reactions were observed among the four groups(P>0.05).Conclusion:Chuzhi Shengfa Tablets combined with ketoconazole shampoo and Chuzhi Shengfa Tablets combined with 5%minoxidil foam are both effective and safe for treating male androgenetic alopecia.These combinations can significantly improve hair growth and are worthy of clinical promotion.展开更多
Objective:To explore the clinical efficacy and safety of Chuzhi Shengfa tablets combined with finasteride in the treatment of male androgenetic alopecia(AGA).Methods:Sixty male patients with androgenetic alopecia admi...Objective:To explore the clinical efficacy and safety of Chuzhi Shengfa tablets combined with finasteride in the treatment of male androgenetic alopecia(AGA).Methods:Sixty male patients with androgenetic alopecia admitted to our Department of Dermatology between January 2022 and January 2024 were randomly divided into two groups,with 30 patients in each group.The control group was treated with finasteride,while the observation group received a combination of Chuzhi Shengfa tablets and finasteride.The clinical efficacy and adverse reactions in both groups were compared.Results:The overall effectiveness rate in the observation group was 93.33%(28/30),significantly higher than the control group’s 73.33%(22/30),with a statistically significant difference(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Chuzhi Shengfa tablets and finasteride shows good clinical efficacy in treating male androgenetic alopecia.Additionally,Chuzhi Shengfa tablets are convenient to administer and effectively improve efficacy,significantly improving patients’conditions,and demonstrating good clinical application value.展开更多
目的:基于网络药理学和分子对接技术初步探讨复方斯亚旦生发酊抗雄激素性秃发(Androgenic Alopecia,AGA)的物质基础及作用机制,为临床应用提供理论基础。方法:通过中药系统药理学数据库与分析平台、中国知网、Pub Med、Swiss Target Pre...目的:基于网络药理学和分子对接技术初步探讨复方斯亚旦生发酊抗雄激素性秃发(Androgenic Alopecia,AGA)的物质基础及作用机制,为临床应用提供理论基础。方法:通过中药系统药理学数据库与分析平台、中国知网、Pub Med、Swiss Target Prediction等数据库收集复方斯亚旦生发酊中3味药材的成分及其对应靶点。利用Gene Cards、Dis Ge NET、OMIM、TTD数据库收集与AGA相关的靶点,得到疾病与药物的共有靶点,然后进行基因本体论(GO)功能注释和京都基因与基因组百科全书(KEGG)通路富集分析。使用Cytoscape构建蛋白质–蛋白质相互作用网络及“药物–成分–靶点–通路”关系,并将复方斯亚旦生发酊的主要活性成分与核心靶点进行分子对接验证。结果:取复方斯亚旦生发酊有效成分与疾病潜在靶点的交集,得到316个共同靶基因,其中关键靶点有热休克蛋白90α家族A类成员1(Heat Shock Protein 90–alpha Family Class A Member 1,HSP90AA1)、信号转导和转录激活因子3(Signal Transducer and Activator of Transcription 3,STAT3)、酪氨酸蛋白激酶Src(Tyrosine–protein Kinase Src,SRC)、雌激素受体α(Estrogen Receptor Alpha,ESR1)、原癌基因c–Jun(Proto–oncogene c–Jun,JUN)等。GO富集分析中生物过程主要包括肽酰酪氨酸修饰、丝裂原活化蛋白激酶(Mitogen–activated Protein Kinase,MAPK)级联的正向调节、激酶活性的正向调节等。KEGG富集分析主要有磷脂酰肌醇3–激酶(Phosphatidylinositide 3–kinases,PI3K)/蛋白激酶B(Akt)、MAPK、RAS相关抑细胞生长蛋白1(Ras–related Protein 1,Rap1)、趋化因子等信号通路。分子对接结果表明核心靶点与复方斯亚旦生发酊中的多数活性成分之间具有较好的结合能力。结论:复方斯亚旦生发酊治疗AGA的机制可能是通过山柰酚、芹菜素、木犀草素、芥子酸、槲皮素等多种成分介导PI3K/Akt和MAPK信号通路中相关蛋白的表达以促进细胞增殖、调节细胞周期、抑制细胞凋亡。展开更多
目的观察生发酊联合当归苦参丸治疗雄激素源性脱发的疗效、安全性及患者满意度。方法将125例患者随机分为生发酊组(A组)62例和生发酊联合当归苦参丸组(B组)63例。A组外用生发酊,每日2次,用药后局部按摩10 m in。B组在A组治疗的基础上口...目的观察生发酊联合当归苦参丸治疗雄激素源性脱发的疗效、安全性及患者满意度。方法将125例患者随机分为生发酊组(A组)62例和生发酊联合当归苦参丸组(B组)63例。A组外用生发酊,每日2次,用药后局部按摩10 m in。B组在A组治疗的基础上口服当归苦参丸,每日2次,每次6 g。观察两组患者的秃发区治疗前后毛发的数量、伴随症状的改善程度与不良反应情况,治疗12个月后根据毛发再生数量判断疗效,根据综合评分的改善程度评价满意度,根据不良事件发生率评判安全性。结果治疗6个月后,B组疗效与A组比较,各项指标差异无统计学意义(P>0.05);治疗12个月后,B组疗效和患者满意度均高于A组(P<0.05);B组的不良事件发生率低于A组(P<0.05)。两组比较,差异有统计学意义。结论生发酊联合当归苦参丸是治疗雄激素源性脱发有效、安全的方法。展开更多
文摘Objective:To investigate the clinical efficacy and safety of Chuzhi Shengfa Tablets combined with ketoconazole shampoo and Chuzhi Shengfa Tablets combined with 5%minoxidil foam in the treatment of male androgenetic alopecia.Methods:From July 2022 to July 2023,120 male patients with androgenetic alopecia were selected from our Department of Dermatology and randomly divided into Control Group 1,Control Group 2,Observation Group 1,and Observation Group 2,with 30 patients in each group.Control Group 1 was treated with ketoconazole shampoo,Control Group 2 with 5%minoxidil foam,Observation Group 1 with ketoconazole shampoo combined with Chuzhi Shengfa Tablets,and Observation Group 2 with 5%minoxidil foam combined with Chuzhi Shengfa Tablets.Hair density,hair diameter,scalp oil secretion(using oil secretion scoring),and adverse reactions were compared before and after treatment across the four groups.Results:After treatment,hair density and hair diameter significantly increased in all four groups compared to before treatment,while scalp oil secretion scores significantly decreased(P<0.05).The improvements in Observation Groups 1 and 2 were significantly better than those in Control Groups 1 and 2(P<0.05).No significant differences in the incidence of adverse reactions were observed among the four groups(P>0.05).Conclusion:Chuzhi Shengfa Tablets combined with ketoconazole shampoo and Chuzhi Shengfa Tablets combined with 5%minoxidil foam are both effective and safe for treating male androgenetic alopecia.These combinations can significantly improve hair growth and are worthy of clinical promotion.
文摘Objective:To explore the clinical efficacy and safety of Chuzhi Shengfa tablets combined with finasteride in the treatment of male androgenetic alopecia(AGA).Methods:Sixty male patients with androgenetic alopecia admitted to our Department of Dermatology between January 2022 and January 2024 were randomly divided into two groups,with 30 patients in each group.The control group was treated with finasteride,while the observation group received a combination of Chuzhi Shengfa tablets and finasteride.The clinical efficacy and adverse reactions in both groups were compared.Results:The overall effectiveness rate in the observation group was 93.33%(28/30),significantly higher than the control group’s 73.33%(22/30),with a statistically significant difference(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Chuzhi Shengfa tablets and finasteride shows good clinical efficacy in treating male androgenetic alopecia.Additionally,Chuzhi Shengfa tablets are convenient to administer and effectively improve efficacy,significantly improving patients’conditions,and demonstrating good clinical application value.
文摘目的:基于网络药理学和分子对接技术初步探讨复方斯亚旦生发酊抗雄激素性秃发(Androgenic Alopecia,AGA)的物质基础及作用机制,为临床应用提供理论基础。方法:通过中药系统药理学数据库与分析平台、中国知网、Pub Med、Swiss Target Prediction等数据库收集复方斯亚旦生发酊中3味药材的成分及其对应靶点。利用Gene Cards、Dis Ge NET、OMIM、TTD数据库收集与AGA相关的靶点,得到疾病与药物的共有靶点,然后进行基因本体论(GO)功能注释和京都基因与基因组百科全书(KEGG)通路富集分析。使用Cytoscape构建蛋白质–蛋白质相互作用网络及“药物–成分–靶点–通路”关系,并将复方斯亚旦生发酊的主要活性成分与核心靶点进行分子对接验证。结果:取复方斯亚旦生发酊有效成分与疾病潜在靶点的交集,得到316个共同靶基因,其中关键靶点有热休克蛋白90α家族A类成员1(Heat Shock Protein 90–alpha Family Class A Member 1,HSP90AA1)、信号转导和转录激活因子3(Signal Transducer and Activator of Transcription 3,STAT3)、酪氨酸蛋白激酶Src(Tyrosine–protein Kinase Src,SRC)、雌激素受体α(Estrogen Receptor Alpha,ESR1)、原癌基因c–Jun(Proto–oncogene c–Jun,JUN)等。GO富集分析中生物过程主要包括肽酰酪氨酸修饰、丝裂原活化蛋白激酶(Mitogen–activated Protein Kinase,MAPK)级联的正向调节、激酶活性的正向调节等。KEGG富集分析主要有磷脂酰肌醇3–激酶(Phosphatidylinositide 3–kinases,PI3K)/蛋白激酶B(Akt)、MAPK、RAS相关抑细胞生长蛋白1(Ras–related Protein 1,Rap1)、趋化因子等信号通路。分子对接结果表明核心靶点与复方斯亚旦生发酊中的多数活性成分之间具有较好的结合能力。结论:复方斯亚旦生发酊治疗AGA的机制可能是通过山柰酚、芹菜素、木犀草素、芥子酸、槲皮素等多种成分介导PI3K/Akt和MAPK信号通路中相关蛋白的表达以促进细胞增殖、调节细胞周期、抑制细胞凋亡。
文摘目的观察生发酊联合当归苦参丸治疗雄激素源性脱发的疗效、安全性及患者满意度。方法将125例患者随机分为生发酊组(A组)62例和生发酊联合当归苦参丸组(B组)63例。A组外用生发酊,每日2次,用药后局部按摩10 m in。B组在A组治疗的基础上口服当归苦参丸,每日2次,每次6 g。观察两组患者的秃发区治疗前后毛发的数量、伴随症状的改善程度与不良反应情况,治疗12个月后根据毛发再生数量判断疗效,根据综合评分的改善程度评价满意度,根据不良事件发生率评判安全性。结果治疗6个月后,B组疗效与A组比较,各项指标差异无统计学意义(P>0.05);治疗12个月后,B组疗效和患者满意度均高于A组(P<0.05);B组的不良事件发生率低于A组(P<0.05)。两组比较,差异有统计学意义。结论生发酊联合当归苦参丸是治疗雄激素源性脱发有效、安全的方法。
